Evidence map›Paper›PMID 40824563›Full record

ArticleWiener klinische Wochenschrift2026

When rash challenges treatment: reintroducing cystic fibrosis modulator therapy safely.

T Vukić Bilić, M Alebić, M Banić, D Darapi, R Likić, M Ganza, D Rnjak, D Tješić-Drinković, A Vukić Dugac

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Wiener klinische Wochenschrift, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

T Vukić BilićClinic for respiratory diseases Jordanovac, University Hospital Center Zagreb, Jordanovac104, 10 000, Zagreb, Croatia.
M AlebićDepartment of Pharmacy, University Hospital Centre Zagreb, Zagreb, Croatia.
M BanićClinic for respiratory diseases Jordanovac, University Hospital Center Zagreb, Jordanovac104, 10 000, Zagreb, Croatia.
D DarapiClinic for respiratory diseases Jordanovac, University Hospital Center Zagreb, Jordanovac104, 10 000, Zagreb, Croatia.
R LikićDivision for Clinical Pharmacology and Therapeutics, Department of Internal Medicine, University Hospital Centre Zagreb, Zagreb, Croatia.
M GanzaDepartment of Pharmacy, University Hospital Centre Zagreb, Zagreb, Croatia.
D RnjakClinic for respiratory diseases Jordanovac, University Hospital Center Zagreb, Jordanovac104, 10 000, Zagreb, Croatia.
D Tješić-DrinkovićSchool of Medicine, University of Zagreb, Zagreb, Croatia.
A Vukić DugacClinic for respiratory diseases Jordanovac, University Hospital Center Zagreb, Jordanovac104, 10 000, Zagreb, Croatia. adugac71@gmail.com.ORCID http://orcid.org/0000-0002-1522-3325

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Various adverse reactions to elexacaftor/tezacaftor/ivacaftor (ETI) therapy have been documented in the literature. Here, we present the first reported case in Croatia of severe rash following ETI therapy in a 19-year-old female cystic fibrosis (CF) patient. There were two attempts to introduce ETI therapy, spaced two months apart, both of which resulted in diffuse maculopapular rash, in the second attempt, the rash appeared on the same day as re-initiation. Given the clinical benefits of ETI treatment, andinspired by several case reports on drug desensitization, in July 2023, we started the patient on a modified 3-day-tolerance induction protocol which was successful.

Indexed as

AminophenolsBenzodioxolesCystic FibrosisDrug EruptionsExanthemaIndolesPyrazolesPyridinesQuinolonesDrug CombinationsFemaleHumansYoung AdultAminophenolsBenzodioxolesDrug CombinationsIndolesPyrazolesPyridinesQuinolonesCystic fibrosisDesensitizationElexacaftor/tezacaftor/ivacaftorRashTreatment

Identifiers

PMID40824563

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.